3Daughters Successfully Closes Over $2 million in First Tranche of Seed Financing Round
Retrieved on:
星期一, 一月 22, 2024
MANSFIELD, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- 3Daughters , a clinical development company fueling evolutionary healthcare for women, announces closing of the first tranche in excess of $2 million in a Seed Round.
Key Points:
- MANSFIELD, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- 3Daughters , a clinical development company fueling evolutionary healthcare for women, announces closing of the first tranche in excess of $2 million in a Seed Round.
- 3Daughters has a unique and frameless delivery platform, based on physics and geometry, for targeted therapy directly into the uterus.
- 3D-001, a novel IUD containing copper, a proven spermicide for contraception, is the first product resulting from the technology.
- This investment marks the next chapter for 3Daughters and allows us to execute our streamlined development plans to move into the clinic.